29 shares 29

0

0



ROKIT Healthcare, a Korean 3D bioprinter manufacturer previously known as ROKIT, has introduced a novel 3D bioprinting method to treat scarred lesions.

Using the company’s 3D bioprinter, the ROKIT INVIVO, to 3D print a patient’s autologous tissues and cells into a dermal patch graft. When placed on a wound, the 3D printed dermal patch graft enables the natural formation of new blood vessels (known as neovascularization) for effective regeneration of the skin.

“It is a novel way of overcoming some of the most pronounced limitations associated with traditional stem cell therapy,” said Seok-Hwan You, Chief Executive Officer of ROKIT Healthcare.

“Utilizing 3D bioprinting techniques allows for effective delivery of autologous cells unto the wound site, minimizing cell loss and greatly enhancing cell viability and proliferation.”

3D bioprinting to heal wounds

According to You, “The current practice of directly injecting expanded or cultured stem cells using syringes severely limits cell viability and accurate, uniformly distributed delivery of effective stem cells unto the disease area.”